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Abstract
Objective
To identify short-term changes in gene expression in peripheral blood mononuclear cells
(PBMCs) associated with treatment response to dimethyl fumarate (DMF, Tecfidera) in
patients with relapsing-remitting MS (RRMS).
Methods
Blood samples were collected from 24 patients with RRMS (median Expanded Disability Status
Scale score, 2.0; range 1–7) at baseline, 6 weeks, and 15 months after the initiation of treatment
with DMF (BG-12; Tecfidera). Seven healthy controls were also recruited, and blood samples
were collected over the same time intervals. PBMCs were extracted from blood samples and
sequenced using next-generation RNA sequencing. Treatment responders were defined using
the composite outcome measure “no evidence of disease activity” (NEDA-4). Time-course and
cross-sectional differential expression analyses were performed to identify transcriptomic
markers of treatment response.
Results
Treatment responders (NEDA-4 positive, 8/24) over the 15-month period had 478 differ-
entially expressed genes (DEGs) 6 weeks after the start of treatment. These were enriched for
nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and inhibition of nuclear factor κB (NFκB)
pathway transcripts. For patients who showed signs of disease activity, there were no DEGs at 6
weeks relative to their (untreated) baseline. Contrasting transcriptomes expressed at 6 weeks
with those at 15 months of treatment, 0 and 1,264 DEGs were found in the responder and
nonresponder groups, respectively. Transcripts in the nonresponder group (NEDA-4 negative,
18/24) were enriched for T-cell signaling genes.
Conclusion
Short-term PBMC transcriptome changes reflecting activation of the Nrf2 and inhibition of
NFκB pathways distinguish patients who subsequently show a medium-term treatment re-
sponse with DMF. Relative stabilization of gene expression patterns may accompany treatment-
associated suppression of disease activity.
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Relapsing-remitting MS (RRMS) is an autoimmune disease
affecting the CNS. Many disease-modifying treatments
(DMTs) are available, but none have efficacy in all patients, all
are expensive, and all are associated with possible adverse
events.1 Stratifying patients to the best tolerated and most
efficacious treatment either before or soon after commencing
treatment would enhance relative benefits and reduce harm.2,3
Currently, themost common approach to ensuring that patients
are receiving efficacious medication involves vigilant disease
monitoring using clinical measures and serial MRI. The most
recent composite “no evidence of disease activity” (NEDA-4)
outcome measure combines 4 indices of disease activity:
relapses, Expanded Disability Status Scale (EDSS) progression,
new MRI activity (Gd+ lesions or new/newly enlarging T2
lesions), and relative brain volume loss.4,5 While sensitive to
disease activity, a limitation of this approach is the time of
observation required to meaningfully assess changes in these
component measures. There is a need for shorter term pre-
dictive markers of clinical outcomes.
Dimethyl fumarate (DMF) (BG-12; Tecfidera) is a first-line
therapy of moderate efficacy approved for use in RRMS. How-
ever, a recent post hoc analysis revealed that only 26% of patients
in the original DEFINE/CONFIRM trials were without clinical
evidence of disease activity or new or enlarging T2-hyperintense
lesions on MRI at 2 years.6 This suggests that there may be
responder and nonresponder populations. However, currently,
there is no early response stratification marker to distinguish
them. The hypothesized mechanism of action involving modu-
lation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2)7,8 and
nuclear factor κB (NFκB)9 in immune cells suggested that
pharmacodynamic effects on the transcriptome of peripheral
blood mononuclear cells (PBMCs) could be used to predict
treatment response.10 To test this, we used next-generationRNA
sequencing to identify short-term changes in gene expression at
6 weeks after treatment initiation that are associated with
medium-term treatment response defined by the composite
outcome measure NEDA-4 at 15 months after treatment.
Methods
Standard protocol approvals, registrations,
and patient consents
Our research study was reviewed and approved by the NHS
Research Ethics Committee of LondonCamden and Islington
(14/LO/1896). All patients provided written informed
consent.
The study cohort included 24 patients with RRMS (median
EDSS score, 2; range 1–7) recruited from the Imperial Col-
lege Healthcare NHS Trust. Inclusion criteria were diagnosis
of RRMS by McDonald criteria,11 age between 18 and 65
years, intent to commence DMF, and otherwise treatment-
free (other DMTs or steroids) for at least 3 months before
sample collection. Exclusion criteria were known or suspected
intolerance or contraindication to MRI. Seven age- and sex-
matched healthy volunteers who were not receiving any
prescribed or over the counter medicines were recruited by
local advertising.
Patients and healthy volunteers attended for 3 study visits. For
patients, these were at baseline, before the onset of treatment,
6 weeks after the initiation of treatment with DMF, and after
15 months of DMF treatment. In the volunteer cohort, there
were also 3 study visits over the same time intervals, but no
drug was taken. The EDSS was conducted by a single, trained
physician (A.R.G.).
Sample collection
Nonfasting venous blood samples were collected at each
study visit in EDTA tubes. PBMCs were extracted from fresh
whole blood within 1 hour of sample collection using a Ficoll
gradient (Histopaque-1077; Sigma Life Science, St. Louis,
MO). Buffy coat containing PBMCs was aspirated using
sterile Pasteur pipettes and washed with sterile phosphate-
buffered saline (PBS). Two wash cycles were performed,
followed by resuspension of cell pellet in 10 mL PBS. Cells
were then counted using Trypan blue, and aliquots of 5–10
million cells were taken for RNA extraction. RNA extraction
was performed on fresh pellet directly after PBMC extraction
using the Qiagen RNeasy kit as per the manufacturer’s
guidelines (Qiagen, Hilden, Germany).
RNA-Seq protocol
RNAwasmaintained at −80°C before sequencing. The quality
of the RNA prepared was confirmed, and all samples were
sequenced at the same time. Quality was assessed as the RNA
concentration measured using a Nanodrop and Qubit 2.0
Fluorometer (Life Technologies, Carlsbad, CA), and RNA
integrity was tested using TapeStation (Agilent Technologies,
Palo Alto, CA). All samples showed a 260-nm/280-nm
Glossary
AR-BVL = annualized rate of brain volume loss; cDNA = complementary DNA;CDP = confirmed disability progression;DE =
differentially expressed;DEG = differentially expressed gene;DMF = dimethyl fumarate;DMT = disease-modifying treatment;
EDSS = Expanded Disability Status Scale; IPA = Ingenuity Pathway Analysis; LFC = log-fold change; LOOCV = leave-one-out
cross-validation; MCS = Mental Component Score; MSFC = MS Functional Composite; NEDA = no evidence of disease
activity; NFκB = nuclear factor κB;Nrf2 = nuclear factor (erythroid-derived 2)-like 2; PBMC = peripheral blood mononuclear
cell; PCS = Physical Summary Score; PBS = phosphate-buffered saline; RRMS = relapsing-remitting MS; SF-36 = 36-item
Short-Form.
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fluorometer intensity ratio of >2 and an RNA integrity
number of >9.
Library preparation was performed using the Illumina NEB-
Next Ultra RNA Library Preparation Kit following the manu-
facturer’s recommendations (NEB, Ipswich, MA). Messenger
RNA was enriched with Oligo d(T) beads and then denatured
for 15 minutes at 94°C. Complementary DNA (cDNA) was
then synthesized, end paired, and adenylated at 39 ends. Then,
a universal adapter was ligated to cDNA fragments along with
the index sequence, and the library was further enriched with
limited cycle PCR. The size of the resulting sequencing libraries
was measured using Agilent TapeStation and quantified using
Qubit 2.0 Fluorometer and quantitative PCR (Applied Bio-
systems, Carlsbad, CA). RNA sequencing was performed on an
Illumina HiSeq platform (San Diego, CA) (2 × 150 base pairs;
paired-end configuration). The quality of the raw sequence
data (Fastq files) was assessed by Phred scoring. The Phred Q
score of 30 was >96% for all samples.
Raw sequences were aligned to the human reference genome
GRCh38.p10 using Dynamic Read Analysis for Genomics
software. Gene hit counts were calculated from the output
BAM files using HTSeq-count, a python library that counts
aligned reads overlapping exons for each gene.12,13 Only reads
mapping unambiguously to a single gene are counted using
the software, and reads possibly mapping to more than 1 gene
are discarded.
MRI scans
The patients with RRMS underwent MRI at the Imperial
College Clinical Imaging Facility at 6 weeks and 15 months
after the start of treatment (Siemens Verio 3T; 32-channel
head coil; T1-and T2-weighted structural scans). Scans were
analyzed using MSmetrix, a scanner-independent and clini-
cally approved software developed by Icometrix to extract
whole brain atrophy, lesion volume changes, and the number
of new lesions between 2 timepoints.14,15 The longitudinal
approach taken by MSmetrix incorporates both spatial and
temporal information for accurate and consistent lesion seg-
mentation based on Markov Random Field modeling and
difference imaging across the 2 timepoints.16
Clinical outcomes
Clinical outcomes of patients were assessed by a single,
trained physician (A.R.G.) before the onset of treatment, 6
weeks after the initiation of treatment with DMF, and after
15 months of DMF treatment (A.R.G.). At each clinical
visit, detailed patient histories were taken including data
concerning any new clinical relapses over the study period,
a full EDSS assessment, MS Functional Composite (MSFC)
scoring,17 and 36-item Short-Form (SF-36)18 quality-of-life
questionnaire.
The NEDA-4 outcome measure was used to designate
patients as responders or nonresponders at 15 months.
NEDA-4 was defined as no evidence of relapses, active MRI
lesions (both new or enlarged T2 lesions), 6-month con-
firmed disability progression (CDP) (defined as an increase in
the EDSS score of 1.5 points from a baseline score of 0, of 1.0
point from a baseline score of 1.0 or more, or 0.5 points from
baseline greater 5.0), or a mean annualized rate of brain vol-
ume loss (AR-BVL) of more than 0.4%.5 Secondary outcome
measures included MSFC Z-score comparisons at baseline
and 15 months. The SF-36 was scored at baseline and 15
months as a Physical Summary Score (PCS) and a Mental
Component Score (MCS).
Statistical analyses
Treatment responders and nonresponders as classified by
NEDA-4 criteria were studied using both time-course and
cross-sectional analyses. Independent differential expression
analyses were performed on count data derived from HT-Seq
using DESeq219 for the responder and nonresponder groups.
DESeq2, which performs differential expression analysis by
first performing a regularized logarithm transformation, fol-
lowed by detection and correction of dispersion estimates that
are too low through modeling using average expression
strength over all samples, was used for this. An assumption
made by this software is that genes of similar average ex-
pression have similar dispersion. Where counts are low or
dispersion is high for a specific gene, DESeq2 shrinks the log-
fold change (LFC) toward zero.20 The software provides an
LFC value across conditions and an adjusted p value corrected
for multiple comparisons using the Benjamini-Hochberg20
method.
Time-course differential expression contrasts were per-
formed between baseline and 6-week samples and then
between 6-week and 15-month samples, using a paired
approach that controlled for intraindividual variations.
Cross-sectional contrasts between patients and controls
were performed, controlling for age as a covariate. Adjusted
p value for significance (Padj) was set at Padj < 0.05. Fold
change cutoffs were thresholded at log2-fold change
of ±0.3.
Downstream pathway analysis was performed using Ingenuity
Pathway Analysis (IPA) software (Qiagen). Genes of interest
imputed into IPA had Padj < 0.05 and log2-fold change of
±0.3. Enrichment analysis was performed using g:Profiler
isolated to KEGG pathways (p < 0.0005).
MSFC Z-score and SF-36 comparisons at baseline and 15
months were calculated using a paired Student t test. Per-
mutation analysis was performed using DESeq2 (100-fold)
with random selection of patients with RRMS (n = 8). The
significance of differences in distributions derived from leave-
one-out cross-validation (LOOCV) was determined using
a Student t test (p < 0.05).
Data availability
Anonymized data will be shared by request from any qualified
investigator.
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Results
Baseline demographics and clinical information of patients
and approximately age- and sex-matched healthy controls are
shown in table 1. Eight patients had been on a previous DMT
(although none received drug in the 3 months preceding
sample collection), and 16 were treatment naive. Two
patients had thalassemia trait, 2 had psoriasis, and 2 had au-
toimmune thyroid disorders. Table e-1, links.lww.com/NXI/
A50 lists concurrent medications taken by patients with
RRMS.
NEDA-4 was achieved by 8/24 patients (33%) over the 15-
month period after initiating treatment with DMF. An AR-
BVL greater than −0.4% (range, −0.44% to −2.19%) was
found for 12 patients (50%). Enlarging or new lesions oc-
curred in 9 patients (38% and 4 of these had an AR-BVL
<−0.4%). Three patients experienced relapses, and 6-month
CDP occurred in 4 patients (2/4 of whom also experienced
relapses).
The median change in the MSFC score from baseline to 15
months for the whole cohort was +0.21 (range, −0.27 to
1.33) (p < 0.005). The median change in the SF-36 PCS was
+4.4 (range, −39.4 to 51.25), and the median change in the
MCS was +2.9 (range, −24.9 to 39.0), but these changes
were not statistically different (p = 0.24 and p = 0.1,
respectively).
Short-term pharmacodynamic effects of DMF
We first tested for differentially expressed gene (DEG) be-
tween the healthy controls and all the patients with MS before
the start of DMF, at baseline. Five hundred twenty-two genes
were differentially expressed (DE) between patients and
controls (Padj < 0.05). Of these, 254 were downregulated in
patients and 268 were upregulated. There was enrichment of
KEGG pathways “B-cell activation involved in the immune
response” and “TNF signaling pathway” (p < 0.001).
We assessed the pharmacodynamic effects of DMF in
patients, independently testing for those in the clinical re-
sponder and nonresponder groups. In the responder group,
there were 478 DEGs 6 weeks after the start of treatment with
DMF relative to baseline (padj < 0.05). These differences
showed enrichment of transcripts related to the Nrf2 pathway
(p < 0.0005) (figure 1) and increased expression of those
associated with inhibiting NFκB responses (overlap p <
0.0005) (figure 2). In the nonresponder group, no consistent
DEGs were identified 6 weeks after the start of treatment
relative to baseline (table 2).
We confirmed the significance of this difference in responder
and nonresponder groups by testing for effects of outlier
values using LOOCV. The median numbers of DEGs after
treatment were 404 and 0 in the responder and nonresponder
groups, respectively (p < 0.0005). We also assessed RNA-Seq
data from untreated healthy controls (n = 7). Comparison
from baseline to the end of a 6-week period without any
intervention showed only 7 DEGs (padj < 0.05) (table 2).
Treatment response is associatedwith a stable
pattern of gene expression
Between 6 weeks and 15 months, 0 and 1,264 DEGs were
detected in the responder and nonresponder groups, re-
spectively (table 2). We further confirmed a difference be-
tween the 2 groups using a 100-fold permutation analysis in
randomly selected combinations of 8 patients with RRMS.
The median number of DEGs in this analysis was 702 (range,
31–3,230). In healthy controls (n = 7), who were not given
any intervention and who were followed up over the same
time period, there were 180 DEGs (table 2).
The large number of DEGs found between 6 weeks and 15
months in the nonresponder group prompted us to test for
response heterogeneity within this group. We first tested for
individual outliers. Based on PCA of the 16 nonresponders at
15 months, responses in 2 patients appeared as outliers and
were therefore removed from further analysis (figure e-1,
links.lww.com/NXI/A48). After the removal of these 2 out-
liers, 2 distinct nonresponder groups (arbitrarily called groups
A and B) were identified in a subsequent round of PCA
(figure e-2). We then independently assessed DEGs between
6 weeks and 15 months in these groups: 560 DEGs were
found for group A and 648 for group B (117 [11%] of these
DEGs overlapped between the 2 groups). We tested for the
significance of these differences relative to the stable expres-
sion pattern in the responder group using LOOCV. The
median numbers of DEGs with LOOCVwere 270 and 497 for
groups A and B, respectively, which both are different to the
equivalent analysis for the responder group, in which the
median number of DEGs was 0 (p = 0.03 and p = 0.004,
respectively).
In group A, the most enriched canonical pathways were in-
volved with Th1 and Th2 activation and T-cell receptor sig-
naling (p < 0.0001). The DEGs showed enrichment for the
Table 1 Patient and healthy volunteer demographic data
Patients with
MS (n = 24)
Healthy
controls (n = 7)
% Women 50% 43%
Mean age (y) 39.6 ± 13.5 36.7 ± 9.7
Average disease duration from
diagnosis (y)
4 ± 4 NA
Average disease duration from
first symptom (y)
7 ± 6 NA
EDSS (median, range) 2 (1–7) NA
Treatment-naive patients 16 NA
Current smoker 2 2
Abbreviations: EDSS = Expanded Disability Status Scale; NA = not applicable.
Values quoted as mean ± SD unless otherwise indicated.
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KEGG pathway “T-cell receptor signaling” (p < 0.0001). A
comparison of patients with healthy controls at 15 months
also demonstrated enrichment of the T-cell receptor signaling
pathway, suggesting that failure to respond well to treatment
is associated with T-cell dysregulation. There were no
enriched canonical or KEGG pathways in group B.
DMF treatment is associated with short-term
relative normalization of gene expression
in responders
After controlling for sex, 668 DEGs were found in samples
from patients in the responder group relative to the healthy
controls at baseline (padj < 0.05). However, 6 weeks after the
start of treatment, only 3 genes were DE between these
patients and the healthy controls (table 3). At 15 months,
there were 85 DEGs between these patients and healthy
controls, although only 14 genes (2%) overlapped with the
DEGs found at baseline (figure 3A).
Four hundred seventy-eight DEGs were found in samples
from patients in the nonresponder group relative to the
healthy controls at baseline (padj < 0.05) (table 3). Ninety-
eight (21%) overlapped with those identified from the re-
sponder group. At 6 weeks after the start of treatment, 18
genes were DE between the nonresponder patients and
healthy controls, 8 of which (44%) also had been identified
baseline (figure 3B). At 15 months, 391 DEGs were found in
nonresponder group A and 340 in nonresponder group B
(table 3).
Discussion
There is currently no reliable early treatment response pre-
diction marker for any RRMS DMT. Here, we explored the
hypothesis that short-term, individual pharmacodynamic
responses can distinguish patients who will respond to DMF.
Figure 1 (A–D) Nuclear factor (erythroid-derived 2)-like 2–related transcripts are increased 6 weeks after treatment in
responders but not in nonresponders or healthy controls
Boxplots represent variance-stabilized transformed counts for transcripts (A) FOSL1, (B) ATF4, (C) MAFG, and (D) MGST1 at baseline and 6 weeks in
responders, nonresponders, and healthy controls. ATF4 = activating transcription factor 4; FOSL1 = fos-related antigen 1; MAFG = transcription factor MafG;
MGST1 = microsomal glutathione S-transferase 1.
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To do this, we tested whether gene expression changes at 6
weeks are associated with the medium-term clinical response
to DMF. Using RNAseq, we observed that a robust short-
term transcriptomic response to DMF in PBMCs was asso-
ciated with activation of the Nrf2 and inhibition of the NFκB
pathways in treatment responders. In addition to a robust
short-term pharmacodynamic response to DMF in treatment
responders, we observed stabilization of gene expression be-
tween 6 weeks to 15 months. By contrast, no early tran-
scriptional changes were observed after starting DMF in
nonresponders. We also found greater expression of proin-
flammatory pathway genes in nonresponders than in healthy
controls.
A number of previous studies also have investigated the
pharmacodynamic effects of DMF on gene expression. These
described modulation of genes related to antioxidant
pathways,21–24 anti-inflammatory pathways,25,26 and
NFκB27,28 that may be related to therapeutic effects. Our
results confirmed changes in expression in all 3 of these
pathways in the subset of patients in whom the drug sup-
presses apparent disease activity. We also demonstrated rel-
ative stabilization of gene expression over the medium term in
Figure 2 (A–D) NFκB-related transcripts are increased 6 weeks after treatment in responders but not in nonresponders or
healthy controls
Boxplots represent variance-stabilized transformed counts for transcripts (A) CD83, (B) ICAM1, (C) NFκBIA, and (D) NFκBIE at baseline and 6 weeks in
responders, nonresponders, and healthy controls. CD83 = cluster of differentiation 83; ICAM1 = intercellular adhesion molecule 1; NFκB = nuclear factor κB;
NFκBIA = nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; NFκBIE = nuclear factor of kappa light polypeptide gene enhancer
in B-cells inhibitor, epsilon.
Table 2 Number of differentially expressed gene
between baseline and 6weeks (short term) and 6
weeks and 15 months (medium term) in
responders, nonresponders, and controls
Responders Nonresponders Controls
Baseline vs 6 wk 478 0 7
6 wk vs 15 mo 0 1,264 180
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treatment responders. By contrast, the nonresponders
showed substantial numbers of DEGs over the same time
period. In a subset of these nonresponders (group A), we
found increased expression of immune activation pathways.
This study identified DEGs between patients with RRMS and
healthy controls at baseline, before treatment. Although some
previous studies also reported DEGs between these
groups,29,30 our use of RNA-Seq allowed a wider range of
discriminatory transcripts to be identified.31 However, PBMC
expression differences between treatment-responsive RRMS
patients and healthy controls did not persist after the initiation
of treatment with DMF. We also provided data suggesting
additional pharmacodynamic effects from stabilization of gene
expression relative to treatment nonresponders. We speculate
that the latter reflects enhanced immune homeostasis and
suggest that the transcriptome differences relative to healthy
controls and their dynamics may be markers of pharmaco-
dynamic response in MS. Supportive evidence for the latter
hypothesis comes from observations of dynamic tran-
scriptome expression with respiratory syncytial virus infection
of an otherwise healthy control monitored with repeated
transcriptomics over 14 months.32
Overall, our treatment response frequency in this pragmatic,
real-world study group was similar to that reported before in
larger populations. We found that 33% of patients achieved
NEDA-4 after 15 months of treatment. This is consistent with
a recent post hoc analysis reporting on the medium-term
NEDA outcomes of the phase III trials (DEFINE/
CONFIRM) of DMF in RRMS.6 We also observed an im-
provement in the overall MSFC score at 15 months, as also
reported from the initial DEFINE/CONFIRM studies.33 Al-
though others have been able to show an improvement in
QOL with DMF as measured by SF-36,34 we were unable to
replicate this finding.
We acknowledge limitations of our work. The small sample
size and using only 3 timepoints limit the confidence in our
selection of transcriptomic response markers and estimation
of their effect size. Further confirmatory work is needed.
However, we attempted to reduce the effect of these factors by
increasing the rigor of our statistical analyses (e.g., performing
LOOCV and permutation tests). The use of a control group at
matching timepoints also allowed us to compare our findings
in the patients with those in a matched, healthy population
Table 3 Number of differentially expressed gene in cross-
sectional analysis between patients with
relapsing-remitting MS and controls at baseline,
6 weeks, and 15 months
Responders
vs control
Nonresponders
vs control
Baseline 668 478
6 wk 3 18
15 mo 85 391 (group A)
340 (group B)
Figure 3 (A–B) Dimethyl fumarate treatment is associated with a relative normalization of gene expression in responders
but not in nonresponders
Venn diagrams represent the number of differentially expressed gene in responder (A) and nonresponder (B) groups compared with controls at baseline, 6
weeks, and 15 months.
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while controlling for potential effects of time. We also mini-
mized the effect of artefacts arising from “batch” effects by
sequencing all samples at the same time and in the same
sequencing facility.
To enhance the power to discriminate responders and the
nonresponders, we used the NEDA-4 criteria, which rely on
the assessment of the apparent rate of brain atrophy. In doing
so over this short time frame (compared with that used for
clinical decision making), we could not formally take into
account the possibility of “pseudoatrophy.” We attempted to
minimize the potential effect of this confound by “rebaselin-
ing” our patients after the initial 6 weeks on medication when
greatest artefactual atrophy might take place.35 To the extent
that we may have misclassified the true treatment response,
this approach will underestimate the efficacy of DMF. How-
ever, the most likely effect of this will be to reduce the sensitivity
to detection of transcriptomic outcomes discriminating treat-
ment responders, rather than to generate false-positive signals.
Finally, although we performed intragroup predictive testing
with leave-one-out cross-validation, without an independent
replication cohort, we were unable to test the predictive power
of our findings formally.
We have provided evidence that DMF can alter PBMC tran-
scriptome profiles of patients withMS even over the short term.
The changes that we found support current hypotheses for
mechanisms of action via activation of Nrf2 and suppression of
NFκB pathways. In addition, we discovered evidence that
a treatment response to DMF is associated with enhanced
immune homeostasis that “normalizes” gene expression in the
PBMC fraction. Validation and extension of these results may
have implications for patient stratification for best use of DMF
in other inflammatory conditions.36,37 Our work highlights the
sensitivity of RNA-Seq transcriptomic pharmacodynamic
measures of drug response. Although the RNA-Seq whole
transcriptome assays of PBMCs now are relatively costly, RNA-
Seq and related methods have the potential to be streamlined
and provided at modest cost to become a future clinical labo-
ratory assay if their value is demonstrated.
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